PMID- 23097651
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121026
LR  - 20211021
IS  - 1671-5411 (Print)
IS  - 1671-5411 (Linking)
VI  - 9
IP  - 3
DP  - 2012 Sep
TI  - A randomized, open-label, multicentre study to evaluate plasma atherosclerotic 
      biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis 
      obliterans when treated with Probucol and Cilostazol.
PG  - 228-36
LID - 10.3724/SP.J.1263.2012.02143 [doi]
AB  - OBJECTIVES: To evaluate the plasma atherosclerotic biomarkers in patients with 
      type 2 diabetes mellitus (T2DM) and arteriosclerosis obliteran (ASO) when treated 
      with Probucol plus Cilostazol in combination and individually. METHODS: In this 
      open-label study, patients aged 40-75 years were randomized to receive 
      conventional therapy alone, or with Cilostazol 100 mg bid, or with Probucol 250 
      mg bid, or with both in combination. Endpoints included changes in plasma 
      biomarker and safety at 12 weeks. RESULTS: Of the 200 randomized patients, 165 
      for per-protocol and 160 for the safety (QTc intervals) were set, respectively. 
      Probucol significantly reduced total cholesterol (P < 0.001), low-density 
      lipoprotein cholesterol (LDL-C), (P = 0.01), and high-density lipoprotein 
      cholesterol (HDL-C) (P < 0.001) compared with conventional therapy. Cilostazol 
      was effective in increasing HDL-C (P = 0.002) and reducing triglycerides levels 
      (P < 0.01) compared with conventional therapy. A trend towards significance was 
      observed for the difference between conventional therapy alone and Probucol plus 
      Cilostazol group for the change in oxidized low-density lipoprotein (Ox-LDL, P = 
      0.065). No significant effects on the majority of the remaining biomarkers were 
      found across the treatment groups. CONCLUSIONS: We have confirmed that Ox-LDL 
      could be a possible plasma atherosclerotic biomarker among the evaluated 
      biomarkers, which reflected the synergetic effect of Cilostazol plus Probucol in 
      patients with T2DM and ASO shown previously in preclinical studies.
FAU - Ma, Xiao-Wei
AU  - Ma XW
AD  - Department of Endocrinology, Peking University First Hospital, No.7 of Xishiku 
      Street, Xicheng District, Beijing 100034, China.
FAU - Guo, Xiao-Hui
AU  - Guo XH
FAU - Xiao, Xin-Hua
AU  - Xiao XH
FAU - Guo, Li-Xin
AU  - Guo LX
FAU - Lv, Xiao-Feng
AU  - Lv XF
FAU - Li, Quan-Min
AU  - Li QM
FAU - Gao, Yan
AU  - Gao Y
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Geriatr Cardiol
JT  - Journal of geriatric cardiology : JGC
JID - 101237881
PMC - PMC3470020
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Biomarkers
OT  - Cilostazol
OT  - Combination treatment
OT  - Probucol
OT  - Synergetic effect
EDAT- 2012/10/26 06:00
MHDA- 2012/10/26 06:01
PMCR- 2012/09/01
CRDT- 2012/10/26 06:00
PHST- 2012/02/14 00:00 [received]
PHST- 2012/08/13 00:00 [revised]
PHST- 2012/08/20 00:00 [accepted]
PHST- 2012/10/26 06:00 [entrez]
PHST- 2012/10/26 06:00 [pubmed]
PHST- 2012/10/26 06:01 [medline]
PHST- 2012/09/01 00:00 [pmc-release]
AID - jgc-09-03-228 [pii]
AID - 10.3724/SP.J.1263.2012.02143 [doi]
PST - ppublish
SO  - J Geriatr Cardiol. 2012 Sep;9(3):228-36. doi: 10.3724/SP.J.1263.2012.02143.